Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia

Launched by PATH · Nov 10, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new test designed to quickly check for a condition called IgG deficiency in patients who have primary immunodeficiency diseases (PID). The researchers want to see how well this test works compared to standard lab tests and whether it can be used with small blood samples taken from a finger prick, as opposed to larger samples taken from a vein. The goal is to improve how we screen for PID, which can help patients get the right treatment more efficiently.

To participate in this study, individuals need to be at least 6 months old and diagnosed with certain types of PID that require monthly treatment with intravenous immunoglobulin (IV-Ig). This includes conditions like agammaglobulinemia and common variable immunodeficiency. The trial is not currently recruiting participants, but when it does begin, those who qualify can expect to have their blood tested using both the new method and the standard method to see how well they match. This could lead to better and faster care for patients with these immune system issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Must be 6 months of age.
• • The types of PID presenting for IV-Ig therapy will include Evaluation of PID RDT with human capillary blood (version 1.0) \| 8agammaglobulinemia (AG), hypogammaglobulinemia (HAG), common variable immunodeficiency (CVID), and hyper IgM syndrome (HIGM).
• Exclusion Criteria:
• • -